Rallybio (RLYB) Competitors $0.60 +0.01 (+1.56%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.59 -0.01 (-1.30%) As of 09/12/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLYB vs. STTK, IPA, CNTB, ANIX, KALA, VIRI, ORMP, MEIP, CRVO, and CRDLShould you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Shattuck Labs (STTK), ImmunoPrecise Antibodies (IPA), Connect Biopharma (CNTB), Anixa Biosciences (ANIX), KALA BIO (KALA), Virios Therapeutics (VIRI), Oramed Pharmaceuticals (ORMP), MEI Pharma (MEIP), CervoMed (CRVO), and Cardiol Therapeutics (CRDL). These companies are all part of the "pharmaceutical products" industry. Rallybio vs. Its Competitors Shattuck Labs ImmunoPrecise Antibodies Connect Biopharma Anixa Biosciences KALA BIO Virios Therapeutics Oramed Pharmaceuticals MEI Pharma CervoMed Cardiol Therapeutics Rallybio (NASDAQ:RLYB) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Does the media prefer RLYB or STTK? In the previous week, Shattuck Labs had 21 more articles in the media than Rallybio. MarketBeat recorded 23 mentions for Shattuck Labs and 2 mentions for Rallybio. Rallybio's average media sentiment score of 1.45 beat Shattuck Labs' score of 0.94 indicating that Rallybio is being referred to more favorably in the media. Company Overall Sentiment Rallybio Positive Shattuck Labs Positive Which has more volatility & risk, RLYB or STTK? Rallybio has a beta of -1.1, indicating that its share price is 210% less volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Is RLYB or STTK more profitable? Shattuck Labs has a net margin of 0.00% compared to Rallybio's net margin of -5,473.33%. Rallybio's return on equity of -71.66% beat Shattuck Labs' return on equity.Company Net Margins Return on Equity Return on Assets Rallybio-5,473.33% -71.66% -65.06% Shattuck Labs N/A -81.80%-71.46% Which has better valuation and earnings, RLYB or STTK? Rallybio has higher earnings, but lower revenue than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRallybio$640K39.23-$57.78M-$0.94-0.64Shattuck Labs$3.00M30.69-$75.41M-$1.21-1.59 Do insiders and institutionals have more ownership in RLYB or STTK? 90.3% of Rallybio shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 8.7% of Rallybio shares are owned by company insiders. Comparatively, 12.0% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate RLYB or STTK? Rallybio presently has a consensus target price of $5.00, indicating a potential upside of 732.22%. Shattuck Labs has a consensus target price of $4.00, indicating a potential upside of 108.33%. Given Rallybio's higher possible upside, research analysts plainly believe Rallybio is more favorable than Shattuck Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Shattuck Labs 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.86 SummaryRallybio beats Shattuck Labs on 9 of the 17 factors compared between the two stocks. Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLYB vs. The Competition Export to ExcelMetricRallybioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.72M$3.19B$5.85B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-0.6421.4375.3425.98Price / Sales39.23429.47514.55181.19Price / CashN/A46.6837.5660.44Price / Book0.409.6112.156.29Net Income-$57.78M-$53.29M$3.29B$271.07M7 Day Performance-1.28%0.13%0.74%3.87%1 Month Performance12.22%5.61%4.82%4.88%1 Year Performance-46.83%10.49%60.58%26.12% Rallybio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLYBRallybio3.3969 of 5 stars$0.60+1.6%$5.00+732.2%-45.4%$24.72M$640K-0.6440Positive NewsShort Interest ↓STTKShattuck Labs3.9219 of 5 stars$2.03+7.7%$4.00+97.5%-48.0%$97.00M$5.72M-1.67100News CoverageAnalyst UpgradeShort Interest ↓Analyst RevisionIPAImmunoPrecise Antibodies2.6317 of 5 stars$2.10+8.5%$4.00+90.9%+222.8%$96.68M$17.59M-3.0880Upcoming EarningsGap UpCNTBConnect Biopharma3.8781 of 5 stars$1.72-4.4%$7.00+307.0%+30.0%$95.84M$26.03M0.00110Short Interest ↓Analyst RevisionANIXAnixa Biosciences3.1049 of 5 stars$2.97-0.5%$9.00+203.5%-11.7%$95.50M$210K-7.805News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionKALAKALA BIO3.8849 of 5 stars$13.53-6.5%$17.25+27.5%+215.6%$94.81M$3.89M-1.9930News CoverageAnalyst ForecastVIRIVirios TherapeuticsN/A$4.90flat$5.00+2.0%+2,484.1%$94.36MN/A-18.155ORMPOramed Pharmaceuticals0.7369 of 5 stars$2.29-0.4%N/A+2.1%$93.89M$1.34M-6.5410MEIPMEI Pharma0.9724 of 5 stars$2.83-5.8%N/A+4.2%$93.06MN/A-0.60100Upcoming EarningsGap UpHigh Trading VolumeCRVOCervoMed3.8254 of 5 stars$10.00+0.1%$19.29+92.9%-47.9%$92.49M$9.74M-3.834Positive NewsAnalyst RevisionCRDLCardiol Therapeutics2.3224 of 5 stars$1.08+2.4%$8.00+644.2%-54.9%$89.99MN/A-3.1620Short Interest ↑ Related Companies and Tools Related Companies Shattuck Labs Alternatives ImmunoPrecise Antibodies Alternatives Connect Biopharma Alternatives Anixa Biosciences Alternatives KALA BIO Alternatives Virios Therapeutics Alternatives Oramed Pharmaceuticals Alternatives MEI Pharma Alternatives CervoMed Alternatives Cardiol Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLYB) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLYB Stock Alerts